
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is well positioned because it has repeatedly beaten modest expectations, raised guidance for the third time this year, and delivered stronger margins, with 3Q revenue of $1,949M, adj. GM% of 57.1%, adj. OM% of 19.9%, and EPS of $1.45. Its outlook is further supported by the shift to a simpler portfolio after the purification and filtration sale and the planned HIS separation, while MedSurg—now about 64% of revenue—still has meaningful penetration opportunities in infection prevention and wound care. Management also reduced near-term cost risk by resolving the 3M supply agreement headwind, and it expects organic growth, margin expansion, and free cash flow to improve as separation-related costs roll off.
Bears say
Solventum is facing a challenging setup because downside to estimates could come from slower growth in its key segments, especially with medsurg now representing roughly 64% of revenue and the dental solutions and health information systems businesses each contributing about 18%. Margin expansion may also lag if operating improvements slow, while higher interest rates could keep interest expense elevated and pressure earnings quality. Competitive intensity in core categories, along with any negative updates on the separation of the HIS segment, adds further uncertainty to the company’s outlook.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Solventum Corporation (SOLV) Forecast
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares